NEW DELHI - Ranbaxy Laboratories' board Feb. 19 approved setting up a research unit called Ranbaxy Life Science Research Ltd., the latest foray by Indian generic pharma firms to create dedicated research and development arms to cut expenses on the parent balance sheet and attract new contract business
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
